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Abstract We assessed the effect of increasing experience
of a single surgeon (learning curve) in the laparoscopic
staging procedure for women with early ovarian cancer and
compared the results with the literature. We retrospectively
analysed a total of 25 women with apparent early-stage
ovarian cancer who underwent a laparoscopic staging
procedure by the same surgeon. Three time periods, based
on date of surgery, were compared with respect to operating
time, amount of lymph nodes harvested and surgical
outcome. There was no significant difference in operation
time, estimated blood loss and hospital stay between the
three periods. There was, however, a significant increase in
the median number of pelvic and para-aortal lymph nodes
harvested (group1=6.5, group 2=8.0 and group 3=21.0;
P<0.005). For the total period, median operation time was
235 min and median estimated blood loss was 100 ml. The
median length of hospital stay was 4.0 days. Two intra-
operative and two postoperative complications occurred.
The upstaging rate was 32%. The mean interval between
initial surgery and laparoscopic staging was 51.2 days.
Mean duration of follow-up was 43 months, range (1–
116 months). Five (20%) patients had recurrences, and
two (8%) patients died of the disease. In conclusion, there
is a significant learning curve for the laparoscopic full
staging procedure in ovarian cancer. In our study this is
mainly reflected in the amount of lymph nodes harvested
and not in the total operating time.
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Background
The risk of an unexpected ovarian malignancy is estimated to
be 1% or less in premenopausal women and 3.0% in
postmenopausal women [1]. The majority of these adnexal
cysts and masses are managed by general gynaecologists,
which may lead to inadequate staging of ovarian cancer
during the primary operation [2, 3]. As a consequence these
patients have two options: (1) second surgery to be optimally
staged since optimal staging is an independent prognostic
parameter for survival or (2) chemotherapy, since non-
optimal staged patients benefit from adjuvant chemotherapy
[4]. In patients there are subgroups who have little or nothing
to gain from adjuvant chemotherapy and it appears to be safe
to withhold adjuvant chemotherapy from patients with early-
stage disease who are optimally staged [5].
The traditional procedure for staging ovarian cancer is
through laparotomy with a midline incision, exposing the
whole peritoneal cavity [6]. Since 1994 several mainly
small studies have been published by a limited group of
centres on the results of a laparoscopic approach to the
staging of early ovarian cancer [7–22]. Laparoscopic
staging proves to be accurate and feasible in ovarian cancer
patients and has the advantages of minimal invasive
surgery. These advantages include less blood loss [8, 17,
18, 21], optical magnification of laparoscopic inspection
[12, 14, 17], shorter hospital stay [8, 10–12, 16–18, 21],
shorter time interval to adjuvant chemotherapy [10, 17] and
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DOI 10.1007/s10397-011-0692-6faster return of bowel movements [17, 18]. Laparoscopic
staging provides similar complication rates as open surgery
[8, 16]. Despite studies proving the feasibility, accuracy and
safety of laparoscopic staging in early ovarian cancer,
laparotomy is still advocated by the majority of centres.
One of the reasons for a slow implementation of minimal
invasive techniques in complex oncological surgery may be
a long learning curve. The learning curve of the laparo-
scopic staging procedure in ovarian cancer has never been
addressed. However Eltabbakh et al. demonstrated clearly a
learning curve in the laparoscopic staging procedure for
endometrial cancer [23]. Our study primarily focuses on the
learning curve of a single surgeon in the laparoscopic
staging procedure in women with early ovarian cancer and
the surgical outcome of these patients.
Patients and methods
A retrospective chart review was undertaken and identified
25 cases of laparoscopic staging of apparent early-stage
ovarian cancer, all operated by the same surgeon (RV) in the
period from June 2001 to October 2009. To obtain clinical
and pathologic information, we reviewed the patient's
medical records. The following information was obtained:
age, BMI, surgical procedure, pre- and postoperative FIGO
stage, histopathology, days between first operation and
staging laparoscopy, operation time, estimated blood loss,
number of pelvic and para-aortic nodes, complications,
hospital stay, nature of subsequent treatment, delay in
chemotherapy, length of follow-up, recurrence and mortal-
ity. Postoperative complications were defined as occurring
within 30 days after the procedure. Most ovarian carcino-
mas were diagnosed at final histopathology, after a first
operation where a malignancy was not anticipated. After
the final pathologic diagnosis, patients were scheduled for a
laparoscopic staging procedure. Preoperative investigations
after the diagnosis of malignancies included: CA 125
measurement, ultrasound and CT scan. All but two patients
were clinically expected to have stage I disease, the other
two patients were expected to have stage II disease. All
histological types of ovarian cancers were included. Patient
characteristics are shown in Table 1.
Laparoscopic staging procedure
All patients were operated by the same surgeon, using the
same technique. Four trocar ports were used. The first 11-mm
trocar was inserted into the umbilical area, one 10-mm trocar
above the symphysis, one 10-mm at the left upper quadrant
and a 5-mm trocar at the right upper quadrant of the lower
abdomen. A thorough exploration of all pelvic and abdominal
organs and peritoneal surface was conducted. Cytological
washings of the peritoneal cavity were taken, and any
suspicious lesion was biopsied next to random biopsies from
the diaphragm, left and right paracolic gutter, peritoneal
reflection of the bladder and pouch of Douglas. Residual
adnexal tissue and/or the residual infundibulo-pelvic ligament
on the side of the originally involved ovary was removed.
Comprehensive surgical staging further involved transperito-
neal lymph node sampling from the pelvic and para-aortic
regions up to the left renal vein, followed by an infra- or
supracolicomentectomy (usinga vessel-sealingtechnique). A
hysterectomy was not routinely performed. The uninvolved
ovary, when unsuspicious on visual inspection, was left in
situ in fertility-sparing procedures, in which case a wedge
biopsy was taken.
Table 1 Patient characteristics
Characteristics Number
Patients 25
Mean age in years (range) 49.7 (18–79)
BMI in kg/m
2 (range) 24.6 (17.4–36.5)
Histological types
Adenocarcinoma 16
Clear cell 4
Borderline 4
Other 1
FIGO stage (before staging)
IA 12
IB 1
IC 9
IIC 2
Unknown 1
Tumour grade
Grade 1 10
Grade 2 7
Grade 3 5
Unknown 3
Procedures at initial surgery
Cystectomy 3
Adnectomy 11
Bilateral adnectomy 5
Hysterectomy + adnectomy 1
Hysterectomy + bilateral adnectomy 4
No initial surgery 1
Ovarian preservation procedure at secondary
surgery
4
Mean age in years (range) 32.3 (18–41)
Histologic type
Borderline 2
Adenocarcinoma 2
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To assess the effect of increasing experience, of the surgeon
in the laparoscopic staging procedure, the patients were
arranged in chronological order based on the date of their
staging surgery. The patients were divided in equal groups
according to three periods. Group I (n=9) had surgery in
2001–2003, group II (n=8) had surgery in 2004–2006 and
group III (n=8) had surgery in 2007–2009. The groups
were compared for surgical outcomes: operating time,
estimated blood loss, number of lymph nodes harvested,
complications and hospital stay.
Literature search
A PubMed search was performed to retrieve all articles
concerning laparoscopic staging procedures in women with
ovarian cancer between 1980 and January 2010. Search terms
used included: ‘ovarian cancer’, ‘early ovarian cancer’,
‘early-stage ovarian cancer’, ‘ovarian carcinoma’, ‘ovarian
neoplasm's’, ‘adnexal tumor’, ‘fallopian tube neoplasm’s’,
‘fallopian tube cancer’, ‘laparoscopy’, ‘laparoscopic sur-
gery’, ‘staging’, ‘staging surgery’ and ‘laparoscopic staging’.
The relevant studies we found were compared to our series
on the basis of above parameters.
Statistical analysis
To analyse non-continuous variables we used the Kruskal–
Wallis test. P values <0.05 were considered significant.
Statistic analysis was performed using the statistical
software package SPSS 15.0 (SPSS Inc, Chicago, IL).
Findings
A total of 25 patients underwent laparoscopic staging for
presumed early-stage ovarian cancer. Most patients (n=24)
had a secondary staging (restaging) procedure after referral,
one patient was primarily staged. Patient's characteristics
are outlined in Table 1. The surgical outcome is outlined in
Table 2. The median operation time was 235 min (range
100–285, mean 224). Intraoperative complications were
two arterial bleedings. One patient lost 1,000 ml of blood,
the other patient 1,500 ml and required a blood transfusion
during surgery. No conversion to laparotomy was needed.
Postoperative complications were two port site haematomas
in different patients, which resolved spontaneously. In 19
patients pelvic lymph nodes were collected (median 8.0,
mean 12.2) and in 24 patients' para-aortic lymph nodes
were collected (median 6.0, mean 5.8). The median
number of total lymph nodes harvested was 8.0 (range
3–31, mean 12.2).
The operating time and total number of lymph nodes
collected are shown in a scatter plot chronologically
arranged by date of surgery (Fig. 1). The operating times
are widely spread, but the total number of lymph nodes
harvested show an increase during time. Based on final
pathological assessment, eight patients were upstaged.
From presumed stage IA, two patients were upstaged to
stage IC, one to stage IIB, one to stage IIC, one to stage
IIIA, two patients were upstaged from presumed stage IC to
stage IIIC and one patient was upstaged from IIC to stage
IIIC. Eleven patients did not need adjuvant chemotherapy;
all other patients received adjuvant chemotherapy. These
patients all had stage IC or higher or a grade 3 tumour.
Mean duration of follow-up was 43 months. Five patients
had a recurrence. One mucinous borderline tumour (2001
FIGO stage IC, no lymph node dissection) and four
carcinomas recurred. In two patients recurrence appeared
as carcinomatous pleuritis or peritonitis. Both these patients
were completely staged and had a clear cell carcinoma
(2003 FIGO IIC and 2006 FIGO stage IC); they died from
the disease. The other patients are all alive without disease.
To demonstrate a possible learning curve over time, the
patients were divided into three groups and compared with
respect to operating time, estimated blood loss, hospital
stay and number of pelvic and para-aortic lymph nodes.
Median operating time, estimated blood loss and hospital
stay did not show a significant difference between the three
groups. But there was a significant increase in the total
number of lymph nodes collected (P=0.003, Table 3).
Table 4 shows an overview of the original literature
Table 2 Surgical outcome
Variable
Operation time (min) 235 (100–285)
Estimated blood loss (ml) 100 (10–1,500)
Total LNN
a
Pelvic lymph nodes (n=19) 8.0 (3–31)
Para-aortic lymph nodes (n=24) 6.0 (2–12)
Overall (n=24) 8.0 (3–31)
Time between operations (days) 54±21
Upstaging (n) 8 (32%)
Intraoperative complications (n) 2 (8%)
Postoperative complications (n) 2 (8%)
Postoperative hospital stay (days) 4.0 (2–6)
Time to adjuvant chemotherapy (days) 21 (±10.3)
Follow-up (months) 43 (±31.5)
Data are expressed as median (range), mean±standard deviation or
number (in percentage)
aIn those patients where a pelvic and/or para-aortic lymphadenectomy
was performed
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Discussion
We expected that with increase of the surgeon's experience in
performing laparoscopic staging procedures, the effect would
be a shorter operating time and a higher number of pelvic
and para-aortal lymph nodes harvested. However we did not
find a decrease in operating time as a function of the
surgeon's experience in laparoscopic staging. This might be
due to the relatively limited number of cases. We did find a
significant increase in the amount of lymph nodes harvested.
The variation in operating time may be due to differences in
the extent of surgery performed during laparoscopic staging.
In the relatively small group we were unable to correct for
these differences. Depending on what is done at initial
surgery, the staging procedure for early ovarian cancer
should be completed at the second operation (restaging). In
our series all patients had an omentectomy, which was
usually performed infracolicly. In nine patients a unilateral
and in three patients, a bilateral salpingo-oophorectomy was
performed, four patients had an ovarian excision (to preserve
fertility) and in nine patients, a bilateral salpingo-
oophorectomy had already been performed during the initial
surgery. In six patients (four carcinomas and two borderline
tumours, all before 2004), there was no pelvic lymphade-
nectomy performed. In the earlier years, less emphasis was
laid on the role of pelvic lymphadenectomy and during the
years, the guidelines changed. In one patient, with a
borderline tumour, a para-aortic lymphadenectomy was not
performed. In one patient a hysterectomy was performed,
and two patients had an appendectomy because of a
mucinous tumour. A laparoscopic procedure including a
hysterectomy takes longer. Childers et al. found a mean
operating time of 149 min in patients who did not undergo a
hysterectomy during their laparoscopic staging, and a mean
operating time of 196 min in patients who did undergo a
hysterectomy [9]. We do not routinely perform a full
hysterectomy in a laparoscopic staging procedure. In view
of the lack of evidence that the uterus may be involved when
the tumour (seemingly) does not extend beyond the ovaries,
it is not justifiable to routinely include such, potentially
harmful, operation [24, 25]. However in a case of endomet-
roid ovarian carcinoma, we perform an endometrial curet-
tage. We did not find recurrences in a retained uterus,
confirming that it is safe to leave the hysterectomy.
Regarding fertility-sparing surgery in early ovarian cancer,
several authors reported that it seems to be safe to leave the
uterus and the remaining ovary [15]. Despite the fact that we
couldn't find a decrease in operating time, it is likely that the
increase of lymph nodes harvested demonstrates a learning
curve in the laparoscopic management of women with early-
stage ovarian carcinoma. This aspect of the learning curve
was also found by Eltabbakh et al. In this study, a
laparoscopic assisted vaginal hysterectomy with bilateral
salpingo-oophorectomy and pelvic lymph node sampling
was performed in patients staged for endometrial cancer.
Next to a significantly reduced operating time, the authors
describe a significant increase in the amount of pelvic lymph
nodes harvested with gaining experience [23].
Although there are studies proving laparoscopic staging
to be accurate and feasible [8, 10–12, 14, 16–18, 21], many
gynaecologic oncologists are still reluctant to adopt
laparoscopic staging of ovarian cancer. Apart from inexpe-
rience with minimal invasive surgery, reluctance seems
mainly based on doubts about the adequacy of the
procedure. In particular to the number of lymph nodes
obtained, possible risk of port site metastases, lack of tactile
Fig. 1 Operating time and number of lymph nodes. Surgical
procedures in chronological order: operating time (n=25) and total
number of lymph nodes [pelvic + para-aortal (n=24) (scatter plot)]
92 Gynecol Surg (2012) 9:89–96sensation and risk of intraoperative mass rupture have been
questioned [8, 11, 12, 16–18, 22].
Several studies found similar numbers of lymph nodes
obtained during laparoscopic and laparotomic staging [11, 21].
The overall number of lymph nodes obtained in our study is
lower than in other studies. This could be due to the fact that
we describe the learning curve from the first case. In other
studies the surgeons are already experienced in the laparo-
scopic staging procedure and completed their learning curve
before the series they describe. This is substantiated by the
fact that the mean number of lymph nodes in the last eight
patients (group 3) is indeed comparable with other authors.
Besides we do not routinely perform a full lymph node
dissection, but rather a sampling. In retrospect, the number of
lymph nodes harvested in the first periods was too low. Future
surgeons can avoid this by learning the procedure from a
gynaecologic surgeon who already performed many lymph
node dissections. Another concern is the risk of port site
metastases due to direct wound contamination or implantation
by instruments [17]. Nagarsheth et al. demonstrated that the
risk of port site metastases (ranging from 0% to 2.3%) is
comparable to the incidence of implantation metastases
observed after conventional laparotomy [18, 26]. The risk
seems to be higher in patients with recurrent ovarian cancer or
primary peritoneal malignancies in the presence of ascites [16,
26]. In our study no port site metastases were seen.
Intraoperative mass rupture in the primary laparoscopic
staging procedure of early-stage ovarian cancer is also been
thought to be a risk [27]. However in secondary staging
procedures, there is no risk of intraoperative mass rupture,
since the tumour has already been removed in the first
procedure. Intraoperative mass rupture leads to subsequent
contamination of the peritoneal cavity with tumour cells
and upstages the unexpected ovarian cancer from stage IA
to stage IC. Upstaging of the tumour can create the need for
adjuvant chemotherapy in patients with potentially curable
disease [18]. A multivariate analysis showed that capsular
rupture caused by the surgeon did not significantly affect
the prognosis in stage I and II ovarian cancer [28]. In
contrast to many others, Vergote et al. reported in a larger
multivariate analysis that tumour rupture during surgery has
a negative effect on prognosis [29]. However, whether or
not tumour rupture has a prognostic effect, it should not be
considered specific to the laparoscopic procedure. The
incidence of iatrogenic rupture of ovarian cancer cysts is
similar in the laparoscopy and laparotomy groups [17, 19].
The rate of upstaging (having a higher stage after
secondary staging procedure then presumed after the initial
operation) found in this study is 32%, percentages found in
other studies range between 0% (only nine patients
described) [20] and 41.7% [12]. The high percentage of
41.7% found by Jung et al. is not entirely comparable to
percentages found in other studies because they included a
relatively high percentage of primary staging procedures.
Our upstaging percentage is similar to upstaging rates in
laparotomic staging ranging from 21.2% [17] to 47% [21].
The mean operation time in our series is comparable to the
operatingtimesreportedbyotherauthors,rangingfrom149to
377 min [9, 11]. The operating times found in studies with a
laparotomy control group range from 218 to 290 min [18,
21]. The operation time for the laparoscopic procedures is
generally longer than for a laparotomy. This should however
be weighted against the patients' benefit from a less
traumatic technique, quicker recovery, shorter hospitalisation
and the opportunity to start chemotherapy earlier [10].
Inthe literature, postoperative stayfor laparoscopicstaging
ranges from 2 to 10.6 days [12, 30]. We found a median of
4.0 days (range 2–6 days). Jung et al. found a mean
postoperative stay of 10.6 days, which is substantially longer
than in the most other studies. The postoperative stay in the
laparotomic control groups ranges 5.8–14.5 days [8, 17].
In our series, four complications occurred. The complica-
tion rate for the laparoscopic staging procedure in early-stage
ovarian cancer found in the literature ranges from 4.2% [12]
to 37.5% [7]. The complication rate in laparoscopy is similar
to or even less compared with laparotomy [8, 11].
Conclusion
This study is primarily focused on the effect of increasing
experience of a single surgeon (‘learning curve’) in the
Table 3 Surgical outcome in time periods
Group I (first period), n=9 Group II (second period), n=8 Group III (third period), n=8 P value
Operative time (min) 225.0 (100–260) 245.0 (145–285) 207.5 (181–270) 0.095
EBL (ml) 50.0 (10–1,000) 50.0 (20–200) 100.0 (20–1,500) 0.682
Total number lymph nodes
a 6.5 (3–17) 8.0 (3–21) 21.0 (7–31) 0.003
Pelvic
a 7.5 (1–12) 3.0 (1–13) 13.0 (4–19) 0.023
Para-aortic
a 5.5 (2–7) 4.0 (2–8) 9.0 (3–12) 0.017
Hospital stay (days) 3.0 (2–5) 4.0 (3–6) 3.5 (3–6) 0.069
Data expressed as medians with range
aIn those patients where a pelvic and/or para-aortic lymphadenectomy was performed
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We demonstrated a significant learning curve for the
laparoscopic full staging procedure in early ovarian cancer.
In our study the effect of the increased experience of the
surgeon is mainly reflected in the increased number of
lymph nodes harvested and not by the total operating time.
Minimal invasive surgery requires a high level of skill and
delicate dissection, and many gynaecologic oncologists
have not yet been trained in this procedure. The laparo-
scopic staging procedure is a complex procedure and
should best be learned under direct supervision of a skilled
gynaecologic laparoscopic surgeon. If more gynaecologic
oncologists would develop their experience with laparo-
scopic staging, this could have a great impact on applying
laparoscopic surgery on a wider scale among women with
early-stage ovarian cancer.
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